SCLC subtyping is more important clinically because the therapeutic potential of inhibitors targeting delta‐like protein 3 (DLL3), an actionable target of ASCL1, is currently under further investigation in clinical trials.35 This evidence concerns the gene ASCL1 and small cell lung carcinoma.